Previous 10 | Next 10 |
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of...
Seer (SEER -3.0%) stock fell despite Q4 revenues rose 812.5% Y/Y to $3.07M. The increase was due to growth in sales of the Proteograph Product Suite, including SP100 instruments, consumable kits and product evaluations in the fourth of quarter of 2021. Product-related revenue was $3...
Image source: The Motley Fool. Seer, Inc. (NASDAQ: SEER) Q4 2021 Earnings Call Feb 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Seer, Inc. (SEER) Q4 2021 Earnings Call Transcript
Seer, Inc. (SEER) Q4 2021 Earnings Conference Call Feb 28, 2022, 04:30 PM ET Company Participants Carrie Mendivil - IR Omid Farokhzad - Founder, Chairman & CEO David Horn - CFO Conference Call Participants Tycho Peterson - JPMorgan Tejas Savant - Morgan Stanley Derik De Bruin - Bank of Am...
Seer press release (NASDAQ:SEER): Q4 GAAP EPS of -$0.32 in-line. Revenue of $3.1M (vs. $336K in Q420) beats by $0.87M. 2022 Guidance: Seer expects full year 2022 revenue to be in the range of $14M to $16M (consensus: $14.84M). In 2022, Seer also expects to continue to increase investments in ...
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “This has been a m...
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating virtually in the upcoming Cowen 42 nd Annual Health Care Conference...
REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, Februa...
REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced Broad Commercial Release of its Proteograph Product Suite and the launch of its Centers of Excellence program. ...
REDWOOD CITY, Calif. and HUNTSVILLE, Ala. and FRAMINGHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics; SCIEX, a global leader in life science analytical technologies; and Discovery Life S...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company manag...
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions REDWOOD CIT...
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to da...